RXRX Q3 2025 Earnings — Recursion Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

RXRXRecursion Pharmaceuticals, Inc.

$2B

Q3 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$5M-80.2% YoY

Gross Profit

-$24M-471.8% margin

Operating Income

-$172M-3327.6% margin

Net Income

-$162M-3135.3% margin

EPS (Diluted)

$-0.36

QoQ Revenue Growth

-72.9%

Cash Flow

Operating Cash Flow

-$117M

Free Cash Flow

-$118M

Stock-Based Comp.

$25M

Balance Sheet

Total Assets

$1.4B

Total Liabilities

$353M

Stockholders' Equity

$1.0B

Cash & Equivalents

$660M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$5M	$26M	-80.2%
Gross Profit	-$24M	$14M	-274.4%
Operating Income	-$172M	-$98M	-75.1%
Net Income	-$162M	-$96M	-69.6%

Revenue Segments

License and Service

$5M96%

Grant

$192,0004%

Geographic Segments

UNITED STATES

$1M100%